NOW APPROVED
CRYSVITA for tumor-induced osteomalacia (TIO)

 

CRYSVITA targets FGF23, the underlying cause of chronic hypophosphatemia in patients with TIO1

 
See Prescribing Information
 

CRYSVITA is the first and only FDA-approved therapy for the treatment of FGF23-related hypophosphatemia in TIO associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.1

 

CRYSVITA was evaluated in two Phase 2 clinical trials of 27 adults with TIO for:

  • Changes in serum phosphorus levels
  • Healing of osteomalacia, as assessed by bone histomorphometry
  • Safety

FGF23, fibroblast growth factor 23.

Still have questions about CRYSVITA for TIO?

Contact us to get in touch with an UltraCare® Liaison who can help answer your questions.

Contact Us

Assistance in gaining access to CRYSVITA treatment

UltraCare offers patient support services that can help your patients understand their insurance coverage, determine eligibility for financial and patient assistance programs, and access resources in patient support. Help ensure your patients have assistance in gaining access to CRYSVITA by filling out the UltraCare Start Form with them and faxing it to 1-415-723-7474.

Download Start Form
Reference

  1. CRYSVITA (burosumab-twza) US Prescribing Information; June 2020.